Compare BioNano Genomics Inc (BNGO) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs PulteGroup, Inc. — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while PulteGroup, Inc. trades at $129.5 (market cap $25.22B). The key difference: PulteGroup, Inc. is far larger — about 1846.3× BioNano Genomics Inc's market cap, and PulteGroup, Inc. pays a 0.79% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PHM | |
|---|---|---|
Market Cap | $13.66M | $25.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $142.56 |
52-Week Low | $1.06 | $110.11 |
Enterprise Value | $16.26M | $25.64B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
PulteGroup (PHM) trades at $129.72, down 0.25% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.20. The company reported Q2 2026 earnings of $2.48 per share, beating estimates, but revenue and margins have softened amid housing market pressures. Recent news highlights operational expansion into Northwest Florida and recognition as a Great Place to Work.
The outlook is mixed: strong cash flow, a solid balance sheet, and share buybacks support the stock, but declining net income margins and affordability challenges pose headwinds. With 43% of analysts rating it a buy, the stock offers moderate upside potential balanced against cyclical housing risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
